

<p>Informazione Regolamentata n. 0957-91-2024</p>	<p>Data/Ora Inizio Diffusione 17 Dicembre 2024 12:26:41</p>	<p>Euronext Milan</p>
---	---	-----------------------

Societa' : DIASORIN

Identificativo Informazione Regolamentata : 199507

Utenza - Referente : DIASORINN01 - Ulisse Spada - Valerio Giovanni Vaccarone

Tipologia : REGEM

Data/Ora Ricezione : 17 Dicembre 2024 12:26:41

Data/Ora Inizio Diffusione : 17 Dicembre 2024 12:26:41

Oggetto : Diasorin S.p.A. - 2025 Annual Calendar of Corporate Events

*Testo del comunicato*

See attachment.

## DIASORIN S.P.A. - 2025 ANNUAL CALENDAR OF CORPORATE EVENTS

Saluggia, - December 17, 2024

### Board of Directors

March 14, 2025	Draft <b>Statutory Financial Statements 2024 and Consolidated Financial Statements 2024</b> approval
May 6, 2025	<b>First Quarter 2025 results</b> approval
July 31, 2025	<b>Half-Yearly Financial Report</b> approval
November 5, 2025	<b>Third Quarter 2025 results</b> approval

### Shareholders' Meeting

April 28, 2025	<b>Annual General Meeting</b> for: (i) 2024 Statutory Financial Statements approval; (ii) appointment of corporate bodies, (iii) Report on the remuneration policy and fees paid approval.
----------------	--

Indicative dates subject to change. Any changes will be communicated without delay.

The Company informs that the month envisaged for the payment of any dividend in relation to 2024 results is May 2025. The information herein reported is given for the exclusive purpose of complying with the relevant Borsa Italiana regulations and cannot be interpreted or considered in any way as a forecast on the occurrence of the requirements for the distribution of dividends.

#### About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 35 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at [www.diasorin.com](http://www.diasorin.com)

**FOR ADDITIONAL INFORMATION, PLEASE CONTACT:**

#### INVESTOR RELATIONS

##### Riccardo Fava

Corporate VP Communication, ESG & Investor Relations  
[riccardo.fava@diasorin.it](mailto:riccardo.fava@diasorin.it)

##### Eugenia Ragazzo

Corporate Investor Relations & ESG Analyst  
[eugenia.ragazzo@diasorin.it](mailto:eugenia.ragazzo@diasorin.it)

Fine Comunicato n.0957-91-2024

Numero di Pagine: 3